The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

Molecular Cell

Volumn 1, Issue 7, 1998, Pages 959-968

  Ohh, Michael ^a   Yauch, Robert L ^a   Lonergan, Kim M ^a   Whaley, Jean M ^b   Stemmer Rachamimov, Anat O ^c   Louis, David N ^c   Gavin, Brian J ^b   Kley, Nikolai ^d   Kaelin Jr , William G ^a,e   Iliopoulos, Othon ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d GENOME THERAPEUTICS CORPORATION   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; LIGASE; PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; CELL LINE; CHEMISTRY; CYTOLOGY; EMBRYO; EXTRACELLULAR MATRIX; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; PROTEIN BINDING; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TRANSFORMED; EMBRYO; EXTRACELLULAR MATRIX; FIBRONECTINS; GENES, TUMOR SUPPRESSOR; HUMANS; LIGASES; MICE; MICE, MUTANT STRAINS; MUTATION; PROTEIN BINDING; PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0032085240     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80096-9     Document Type: Article

References (53)

1. Aso, T., Lane, W.S., Conaway, J.W., and Conaway, R.C. (1995). Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 269, 1439-1443.
2. Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J.W., and Elledge, S.J. (1996). SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274.
3. Bard, J.B.L. (1992). The development of the mouse kidney-embryogenesis writ small. Curr. Opin. Genet. Dev. 2, 589-595.
4. Carone, F., Bacallao, R., and Kanwar, Y. (1994). Biology of disease: biology of polycystic kidney disease. Lab. Invest. 70, 437-438.
5. Chen, L.B., Gallimore, P.H., and McDougall, J.K. (1976). Correlation between tumor induction and the large external transformation sensitive protein on the cell surface. Proc. Natl. Acad. Sci. USA 73, 3570-3574.
6. Corless, C.L., Kibel, A., Iliopoulos, O., and Kaelin, W.G.J. (1997). Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum. Pathol. 28, 459-464.
7. Davies, J. (1993). How to build a kidney. Semin. Cell. Biol. 4, 213-219.
8. Duan, D.R., Humphrey, J.S., Chen, D.Y.T., Weng, Y., Sukegawa, J., Lee, S., Gnarra, J.R., Linehan, W.M., and Klausner, R.D. (1995a). Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA 92, 6495-6499.
9. Duan, D.R., Pause, A., Burgress, W., Aso, T., Chen, D.Y.T., Garrett, K.P., Conaway, R.C., Conaway, J.W., Linehan, W.M., and Klausner, R.D. (1995b). Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269, 1402-1406.
10. Ekblom, P. (1992). Renal development. In The Kidney: Physiology and Pathophysiology, D.W. Seldin and G. Giebisch, eds. (New York: Raven Press, Ltd.), pp. 475-501.
11. Garrett, K., Aso, T., Bradsher, J., Foundling, S., Lane, W., Conaway, R., and Conaway, J. (1995). Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. Proc. Natl. Acad. Sci. USA 92, 7172-7176.
12. George, E., Georges-Labouesse, E., Patel-King, R., Rayburn, H., and Hynes, R. (1993). Defects in mesoderm, neural tube and vascular development in mouse embroyos lacking fibronectin. Development 119, 1079-1091.
13. Giancotti, F.G., and Ruoslahti, E. (1990). Elevated levels of the a5b1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60, 849-859.
14. Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90.
15. Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J., Krumm, A., Papavassiliou, E., Oldfield, E.H., Klausner, R.D., and Linehan, W.M. (1996). Post-transcriptional regulation of vascular endothelial growth factor m RNA by the VHL tumor suppressor gene product. Proc. Natl. Acad. Sci. USA 93, 10589-10594.
16. Gnarra, J., Ward, J., Porter, F., Wagne, J., Devor, D., Grinberg, A., Emmert-Buck, M., Westphal, H., Klausner, R., and Linehan, W. (1997). Defective placental vasculogenesiscauses embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94, 9102-9107.
17. Harlow, E., and Lane, D. (1988). Antibodies: A Laboratory Manual (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory).
18. Harris, P., Ward, C., Peral, B., and Hughes, J. (1995). Autosomal dominant polycystic kidney disease: molecular analysis. Hum. Mol. Genet. 4, 1745-1749.
19. Hay, E. (1995). An overview of epithelio-mesenchymal transformation. Acta Anat. 154, 8-20.
20. Hopkin, K. (1997). Regulating cellular processes: the power of protein degradation. J. NIH Res. 9, 36-42.
21. Hynes, R. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
22. Hynes, R.O., and Destree, A.T. (1978). Relationships between fibronectin (LETS) and actin. Cell 15, 875-886.
23. Hynes, R., Ali, I., Destree, A., Mautner, V., Perkins, M., Senger, D., Wagner, D., and Smith, K. (1978). A large glycoprotein lost from the surfaces of transformed cells. Ann. NY Acad. Sci. 312, 317-342.
24. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G. (1995). Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822-826.
25. Iliopoulos, O., Jiang, C., Levy, A.P., Kaelin, W.G., and Goldberg, M.A. (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93, 10595-10599.
26. Jackson, P.K. (1996). Cell cycle: cull and destroy. Curr. Biol. 6, 1209-1212.
27. Kaelin, W.G. (1997). Recent insights into the functions of the retino-blastoma gene product. Cancer Invest. 15, 243-254.
28. Kassner, P.D., and Hemler, M.E. (1993). Interchangable α chain cytoplasmic domains play a positive role in control in cell adhesion mediated by VLA-4, a β1 integrin. J. Exp. Med. 178, 649-660.
29. Kibel, A., Iliopoulos, O., DeCaprio, J.D., and Kaelin, W.G. (1995). Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269, 1444-1446.
30. Kishida, T., Stackhouse, T.M., Chen, F., Lerman, M.I., and Zbar, B. (1995). Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of mis-sense mutations. Cancer Res. 55, 4544-4548.
31. Kochevar, G., Stanek, J., and Rucker, E. (1992). Truncated fibronectin. Cancer 69, 2311-2315.
32. Kopito, R.R. (1997). ER quality control: the cytoplasmic connection. Cell 88, 427-430.
33. Lee, W.-H., Shew, J.-Y., Hong, F.D., Sery, T.W., Donoso, L.A., Young, L.-J., Bookstein, R., and Lee, E.Y.-H.P. (1987). The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329, 642-645.
34. Lee, S., Chen, D.Y.T., Humphrey, J.S., Gnarra, J.R., Linehan, W.M., and Klausner, R.D. (1996). Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA 93, 1770-1775.
35. Lipkin, G., Knecht, M., and Rosenberg, M. (1978). Glycoprotein-containing factor that mediates contact inhibition of growth. Ann. NY Acad. Sci. 372, 382-391.
36. Lonergan, K.M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R.C., Conaway, J.W., and Kaelin, W.G. (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18, 732-741.
37. Los, M., Jansen, G.H., Kaelin, W.G., Lips, C.J.M., Blijham, G.H., and Voest, E.E. (1996). Expression pattern of the von Hippel-Lindau protein in human tissues. Lab. Invest. 75, 231-238.
38. Lubensky, I.A., Gnarra, J.R., Bertheau, P., Walther, M.M., Linehan, W.M., and Zhuang, Z. (1996). Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol. 149, 2089-2094.
39. Maher, E., and Kaelin, W.G. (1997). von Hippel-Lindau disease. Medicine 76, 381-391.
40. Mathias, N., Johnson, S., Winey, M., Adams, A., Goetsch, L., Pringle, J., Byers, B., and Goebl, M. (1996). Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins. Mol. Cell. Biol. 16, 6634-6643.
41. Mukhopadhyay, D., Knebelmann, B., Cohen, H., Ananth, S., and Sukhatme, V. (1997). The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17, 5629-5639.
42. Nakamura, Y. (1997). Cleaning up on β-catenin. Nat. Med. 3, 499-509.
43. Pasqualini, R., Bourdoulous, S., Koivunen, E., Woods, V. Jr., and Ruoslahti, E. (1996). A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat. Med. 2, 1197-1203.
44. Pause, A., Lee, S., Worrell, R.A., Chen, D.Y.T., Burgess, W.H., Linehan, W.M., and Klausner, R.D. (1997). The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94, 2156-2161.
45. Pause, A., Lee, S., Lonergan, K.M., and Klausner, R.D. (1998). The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA 95, 993-998.
46. Radke, K.V., Carter, C., Moss, P., Dehazya, P., Schliwa, M., and Martin, S. (1983). Membrane association of a 36,000-Dalton substrate for tyrosine phosphorylation in chicken embryo fibroblasts transformed by avian sarcoma viruses. J. Cell. Biol. 97, 1601-1611.
47. Ruoslahti, E. (1991). Integrins. J. Clin. Invest. 87, 1-5.
48. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G., and Marme, D. (1996). Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299-2301.
49. Vaheri, A., Alitalo, K., Hedman, K., Keski-Oja, J., Kurkinen, M., and Wartiovaara, J. (1978). Fibronectin and the pericellular matrix of normal and transformed adherant cells. Ann. NY Acad. Sci. 312, 343-353.
50. Watt, F., and Hodivala, K. (1994). Fibronectin and integrin knockouts come unstuck. Curr. Biol. 4, 270-272.
51. Wu, C., Keivens, V., O'Toole, T., McDonald, J., and Ginsberg, M. (1995). Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell 83, 715-724.
52. Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E.R., Richards, F.M., Crossey, P.A., Webster, A.R., Affara, N.A., Ferguson-Smith, M.A., et al. (1996). Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348-357.
53. Zhuang, Z., Bertheau, P., Emmert-Buck, M., Liotta, L., Gnarra, J., Linehan, W., and Lubensky, I. (1995). A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am. J. Pathol. 146, 620-625.